Stock Analiz

RedHill Biopharma Ltd. RDHL

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$0.38Market cap $3M
Open the interactive analysis →

RedHill Biopharma Ltd. (RDHL) is a healthcare company listed in the US with a market value of about $3M. In fiscal year 2024 it had revenue of $8M and net income of -$8M, a net margin of -102.8%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 5% a year, a 5-year average ROIC of 77%.

About RedHill Biopharma

RedHill Biopharma is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $3000 in 2015 to $8M in 2024, growth of about 140.4% a year. It was profitable in 1 of the last 10 years in our data.

Score: 1.2 / 5

Value0/5
Future growth1/5
Track record2/5
Financial health3/5
Shareholder returns0/5

Checks passed

  • Profit margin improving
  • 5-year average ROIC above 12%
  • ROE above 15%
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.4
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-281.4%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)5.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-112.8%
ROIC (5-yr avg.)77.4%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal year2024202320222021202020192018201720162015
Revenue$8M—$62M$86M$64M$6M$8M$4M$101000$3000
Net income-$8M$24M-$72M-$98M-$76M-$42M-$39M-$46M-$29M-$21M
Free cash flow-$9M-$36M-$29M-$65M-$49M-$41M-$34M-$45M-$28M-$18M
EPS (diluted)$-0.93$2.69$-8.06$-11.00$-8.57$-4.76$-4.37$-5.12$-3.30$-2.37
Net margin-102.8%—-116.0%-114.0%-118.4%-672.5%-464.4%-1136.6%-29079.2%-703000.0%
ROIC—482.3%-50.7%-69.3%-52.8%-56.9%-60.7%-91.1%-38.5%-28.9%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does RedHill Biopharma pay a dividend?

Not currently.

Is RedHill Biopharma a good stock to buy?

We do not give buy or sell advice. RedHill Biopharma scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.